VEGF-A has been implied as a target in several clinically relevant conditions, e.g., ischemia, arthritis, or obesity (Carmeliet, 2003), peripheral artery disease (Clegg et al., 2017), or cancer (MacGabhann and Popel, 2006; Zhang et al., 2010). Here, VEGFA is linked to cancer.